Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS) - The Baytown Sun

Pfizer Announces Positive Phase 3 Study Results for XELJANZ ® (tofacitinib) in Ankylosing Spondylitis (AS)  The Baytown Sun

Comments

Popular posts from this blog

Epstein-Barr virus and autoimmune diseases

Chronic Lyme arthritis: A mystery solved?

Fibromyalgia — Latest Stories — Pain News Network